Filing Flows › Health Care › Agios Pharmaceuticals (AGIO)
Agios Pharmaceuticals (AGIO) earnings and revenue breakdown
Latest: Q3 2026 · 10-Q filed Nov 5, 2026 · Agios Pharmaceuticals (AGIO) Q3 2026 earnings results →
Q3 2026 Revenue up 330% year over year to $55.4M · 117¢ of every $1 of revenue lost · operating margin -139.3%
Agios Pharmaceuticals made $55.4M in Q3 2026 (+330% Y/Y). Operating margin -139.3%, net loss $65.0M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Nov 5, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $55.4M in Q3 2026, up 330% year over year and up 24% from the previous quarter.
Operating costs exceeded revenue by $77.2M, an operating margin of -139.3%. Total costs grew 2% against revenue growth of 330%. The fastest-growing cost line was Cost of revenue (+50%). The quarter ended with a net loss of $65.0M, narrower than the previous quarter's $100.7M loss.
Operating cash flow was −$59.2M. Non-cash charges added back $16.7M of share-based compensation. Working capital and other items used $10.9M. Capital expenditures of $1.2M exceeded it, leaving free cash flow of −$60.4M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q3 2026 | 10-Q | Nov 5, 2026 | $55.4M | +330% | -139.3% | −$65.0M | −$59.2M |
| Q2 2026 | 10-Q | Jul 30, 2026 | $44.7M | +259% | -247.1% | −$101M | −$57.3M |
| Q1 2026 | 10-Q | Apr 29, 2026 | $20.7M | +138% | -530.3% | −$99.1M | −$119M |
| Q4 2025 | 10-K | Feb 12, 2026 | $20.0M | +86% | -608.9% | −$108M | −$96.2M |
| Q3 2025 | 10-Q | Oct 30, 2025 | $12.9M | +44% | -907.4% | −$103M | −$88.2M |
| Q2 2025 | 10-Q | Jul 31, 2025 | $12.5M | +45% | n/m | −$112M | −$77.1M |
| Q1 2025 | 10-Q | May 1, 2025 | $8.7M | +7% | n/m | −$89.3M | −$111M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About Agios Pharmaceuticals
We are a commercial-stage biopharmaceutical company dedicated to redefining the future of rare disease treatment. Fueled by connections, we build trusted partnerships with communities, collaborating to develop and deliver innovative medicines with the potential to transform lives. With a foundation in hematology, we combine biological expertise with real-world insights to advance a growing pipeline of rare disease medicines that reflect the priorities of the people we serve. The lead product candidate in our portfolio, mitapivat, is an activator of both wild-type and mutant pyruvate kinase, or PK, enzymes for the potential treatment of hemolytic anemias. Mitapivat is approved in the United States by the U.S.
In its own words, from its 10-K, filed Feb 12, 2026.
Agios Pharmaceuticals against its Pharmaceutical Preparations peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: +330% against the peers' median +10%. Operating margin: -139.3% against the peers' median 20.4%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| AGIO Agios Pharmaceuticals | Q3 2026 | $55.4M | +330% | -139.3% |
| JNJ Johnson & Johnson | Q3 2026 | $25.4B | +6% | 0.1% |
| LLY ELI Lilly | Q3 2026 | $24.4B | +39% | 34.5% |
| MRK Merck | Q3 2026 | $18.1B | +5% | 30.7% |
| ABBV AbbVie | Q3 2026 | $17.4B | +10% | 36.0% |
| PFE Pfizer | Q3 2026 | $16.6B | -0.4% | 20.4% |
| BMY Bristol Myers Squibb | Q3 2026 | $13.1B | +7% | 19.4% |
| ABT Abbott Laboratories | Q3 2026 | $13.0B | +14% | 10.4% |
| REGN Regeneron Pharmaceuticals | Q3 2026 | $5.1B | +36% | 40.0% |
Source: Agios Pharmaceuticals 10-Q on SEC EDGAR · CIK 1439222 · Pharmaceutical Preparations
Guidance and outlook
13F: who owns AGIO and who is buying
More on AGIO
- How Agios Pharmaceuticals makes money: revenue by segment
- Agios Pharmaceuticals next earnings date and what analysts expect
- Agios Pharmaceuticals stock forecast, price target and fair value
- Who owns Agios Pharmaceuticals stock: holders, funds and Congress trades
- Agios Pharmaceuticals guidance and outlook
- Is Agios Pharmaceuticals a takeover target? LBO and rumors
- Agios Pharmaceuticals recalls, complaints and regulation
History
Every quarter: Q3 2026 results · Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results · Q1 2025 results